Supplementary Appendix

This appendix has been provided by the authors to give readers additional information about their work.

Supplement to: Cardoso F, van't Veer LJ, Bogaerts J, et al. 70-Gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med 2016;375:717-29. DOI: 10.1056/NEJMoa1602253

Supplemental material to Cardoso, van 't Veer, Bogaerts et al Sections

JUUU		
1	Acknowledgments	3
2	Reason registered/screened but not enrolled	4
3	Risk corrections post enrollment	5
4	Outcome in the 4 risk groups	8
5	Distant Metastasis Free Survival according to the genomic and clinical risk treatment strategy	9
6	DMFS for CT versus no CT in the two discordant risk groups (ITT1 population), by nodal status	10
7	DMFS for CT versus no CT in the two discordant risk groups (ITT1 population), by tumor size	11
8	Analyses within the subgroup of HR+/HER2-/LN0 patients	12
9	Multivariate analysis	15
10	Distant Metastasis Free Interval	17
11	Compliance to randomized treatment	18
12	Agreement between local and central pathology	19
13	Clinical risk assessment according to modified Adjuvant!Online	20
14	DMFS, DFS and OS for CT versus no CT in the two discordant risk groups (ITT1 population)	21
15	DMFS in the C-high/G-low risk group in the different analysis populations	22
16	The MINDACT study design	23
Tab	<u>bles</u>	
	ole S 1: Reason enrollment was not successful (screening failure)	
	ole S 2: Risk corrections post enrollment	
	ole S 3: Reason for clinical risk change	
	ole S 4: Reason for genomic risk change	
	ole S 5: Sensitivity analysis excluding period of shift in risk due to change in RNA extraction solution	
	ble S 6: Outcome in terms of DMFS, DFS and OS for the 4 risk groups (per corrected risk)	
	ole S 7: Corrected risk in the subgroup of HR+/HER2-/LN0 patients	
	ole S 8: Outcome per corrected risk in the subgroup of HR+/HER2-/LN0 patients	
	ole S 9: Outcome by genomic risk when following genomic treatment strategy (G-low versus G-high), ir group of HR+/HER2-/LN0 patients	
Tab	ole S 10: Multivariate analysis for DMFS in all enrolled patients	15
Tab	ole S 11: Compliance to randomized treatment as assessed by medical review	18
Tab	ole S 12: Agreement for all patients with available central pathology	19
	ole S 13: Classification of patients according to clinical risk assessment by the modified versio uvant!Online	
Tab	le S 14: DMFS, DFS and OS for CT versus no CT in the two discordant risk groups (ITT1 population)	21
Tab	ole S 15: DMFS the C-high/G-low risk group in the different analysis populations	22
Figu	<u>ures</u>	
Figu	ure S 1: DMFS according to the genomic and clinical risk treatment strategy	9
Figu	ure S 2: DMFS CT versus no CT in the two discordant risk groups (ITT1 population) by nodal status	10

Figure S 3: DMFS CT versus no CT in the two discordant risk groups (ITT1 population) by tumor statu	s 11
Figure S 4 DMFS by genomic risk when following genomic treatment strategy (G-low versus G-high subgroup of HR+/HER2-/LN0 patients	
Figure S 5: DMFS for CT versus no CT in the two discordant risk groups (ITT1 population), in the HR+ /LN0 subgroup	•
Figure S 6: DMFI for CT versus no CT in the two discordant risk groups (ITT1 population)	
Figure S 7: The MINDACT study design	23

1 Acknowledgments

We are grateful to *all patients and families* who participated in this study.

Special thanks to:

All *national coordinating centers and BIG Groups* participating in MINDACT (BOOG, EORTC-BCG, GOIRC, NCRI-BCSG, SOLTI, UNICANCER-UCBG, WSG).

Steering Committee members: Karen Benn, Jan Bogaerts, Fatima Cardoso, Eva Ciruelos, Sabine Corochan, Julia Cuny, Lorena de la Pena, Suzette Delaloge, Mauro DeLorenzi, Aleksandra Dudek-Peric, Inge Eekhout, Oleg Gluz, Vassilis Golfinopoulos, Theodora Goulioti, Nadia Harbeck, Valérie Hilal, Susan Knox, Jerome Lemonnier, Michał Ławniczak, Luca Marini, Erika Matos, Pepi Morales, Kirsten Murray, Urlike Nitz, Rodolfo Passalaqua, Martine Piccart, Jolanda Remmelzwaal, Isabel Rubio, Emiel Rutgers, Mahasti Saghatchian, Leen Slaets, Christos Sotiriou, Carolyn Straehle, Mark Straley, Nathalie Theron, Alastair Thompson, Konstantinos Tryfonidis, Renata Todeschini, Milanka Urunkar, Laura van 't Veer, Giuseppe Viale.

Fellows and clinical research physicians: Kim Aalders, Jacques Bines, Philippe Bedard, Ivana Bozovic, Sofia Braga, Carlos Castaneda, Aleksandar Celebic, Camelia Colichi, Carmen Criscitiello, Lissandra Dal Lago, Gaston Demonty, Caroline Drukker, Fei Fei, Michela Lia, Sherene Loi, Carlo Messina, Stella Mook, Camilo Moulin, Roman Sreseli, Patrick Therasse, Gustavo Werutsky.

EORTC & BIG Project and Data Managers: Sabine Corachan, Aleksandra Dudek-Peric, Lorraine Wheeler, Nicolas Dif, Giovanna Rizzetto, Melanie Beauvois, Livia Meirsman, Hilde Breyssens, Nuria Decker, Kristel Engelen, Anita Akropovic, Jillian Harrison, Frederic Henot, Miet Celis, Britt De Jongh, Inge Delmotte, Valéry Daubie, Roel Goossens, Nils Helsen, Laetitia Hourt, Sven Janssen, Virginie Soete, Kaat Vansevenant, Catherine Hermans.

All *the many academic institutions and collaborators* participating in *TRANSBIG* as well as the scientific or logistical support from Guus Hart, *SIB, IEO, Adjuvant!Online, Agendia (*Guido Brink, Arno Floore, Bernhard Sixt, and all team), *IBBL, IDDI (*Marc Buyse), *and World Courier*.

2 Reason registered/screened but not enrolled

Table S 1: Reason enrollment was not successful	(screening failure)
---	---------------------

Reason for screening failure	All screening failures (N=4595) N (%)
MammaPrint not feasible (mostly <50%/<30% tumor cells)	1182 (26%)
Patient/investigator decision	899 (20%)
Ineligible : LN status	772 (17%)
Inadequate/absent sample	768 (17%)
Ineligible: other	447 (10%)
Unknown or other	527 (11%)

3 Risk corrections post enrollment

C-risk/G-risk at enrollment	C-low/G-? (N=1)	C-low/G-low (N=2744)	C-low/G-high (N=592)	C-high/G-low (N=1550)	C-high/G-high (N=1806)	Total (N=6693)
	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)
C-low/G-low	1 (100.0)	2600 (94.8)	3 (0.5)	30 (1.9)	0 (0.0)	2634 (39.3)
C-low/G-high	0 (0.0)	95 (3.5)	580 (98.0)	0 (0.0)	15 (0.8)	690 (10.3)
C-high/G-low	0 (0.0)	44 (1.6)	0 (0.0)	1450 (93.5)	3 (0.2)	1497 (22.4)
C-high/G-high	0 (0.0)	5 (0.2)	9 (1.5)	70 (4.5)	1788 (99.0)	1872 (28.0)

Table S 2: Risk corrections post enrollment

Legend: For 275 patients (4%) the C and/or G risk supplied at enrollment was corrected later during the trial as shown in the table.

Table S 3: Reason for clinical risk change

Reason for clinical risk assessment change	Total (N=103)
	N (%)
change in tumor size	21 (20.2)
change in tumor grade	19 (18.3)
change in ER status	4 (3.8)
change in HER2 status	12 (11.5)
change in Nodal status	24 (23.1)
clinical risk of LN2/3+ was miscalculated as LN 4/9+	6 (5.8)
clinical risk of 12% was miscalculated as low risk	6 (5.8)
other/combination	11 (10.6)

Legend: For 103 patients the clinical risk status was corrected post-enrollment based on updated patient and tumor characteristics that were received from the site during the study as shown in the table. The patient with unknown genomic risk post enrollment (C-low/G-?) is classified under C-low/G-low (risk per enrollment) in the analyses per corrected risk. For 38 of those 103 patients the clinical risk assessment supplied at time of enrollment lead to an inappropriate treatment strategy allocation. By 'inappropriate' we mean a treatment strategy ('CT' versus 'no CT') that would not be considered as an option for the patient per MINDACT protocol. For example, for patients belonging to the discordant risk groups, both 'CT' and 'no CT' are considered appropriate treatment strategies while for the C-low/G-low group 'CT' would be an inappropriate treatment strategy. Out of these 38 patients, 21 have received an inappropriate treatment as defined in MINDACT: 3 patients were under-treated (did not receive CT when they should have) and 18 were over-treated (received CT when they should not have, as per protocol definition); 5 of the over-treated patients had a change in both clinical and genomic risk.

Table S 4: Reason for genomic risk change

Reason for clinical risk assessment change	Total (N=177) N (%)
Change in RNA extraction solution	153 (86.4)
Sample swap	5 (2.8)
other/combination	19 (10.7)

Legend: For 177 patients the genomic risk status was corrected post-enrollment for reasons tabulated above.

For 56 of these 177 patients, the genomic risk result supplied at time of enrollment lead to an inappropriate treatment strategy allocation. Among these 56 patients, 37 received an inappropriate treatment strategy, as per protocol definition: 2 patients were under-treated (did not receive CT when they should have) and 35 were over-treated (received CT when they should not have); 5 of the over-treated patients had a change in both clinical and genomic risk.

Table S 5: Sensitivity analysis excluding period of shift in risk due to change in RNA extraction solution

	PTS population (excluding G-risk shift period): C-high/G-low – no CT							
Allocated Patients Observed Events (95% CI) Standard error of the				Standard error of the 5 year rate				
	DMFS	no CT	549	33	94.0 (91.5, 95.8)	0.0109		

	PPS population (excluding G-risk shift period): C-high/G-low								
	Allocated Treatment strategy	Patients (N)	Observed Events (O)	% at 5 Year(s) (95% Cl)	Hazard ratio * (95% CI)	p-value **			
DFS	СТ	503	32	93.3 (90.3, 95.4)	0.57 (0.37,0.87)	0.009			
DF3	no CT	542	61	88.8 (85.7, 91.3)	1.00	0.009			
DMFS	СТ	503	18	96.5 (94.1 <i>,</i> 97.9)	0.60 (0.34,1.06)	0.080			
DIVIFS	no CT	542	33	94.0 (91.4, 95.8)	1.00	0.080			
OS	СТ	503	8	98.8 (97.1, 99.5)	0.54 (0.23,1.26)	0.154			
03	no CT	542	17	97.0 (94.9, 98.2)	1.00	0.134			

	PPS population (excluding G-risk shift period): C-low/G-high								
Allocated Treatment strategy		Patients (N)	Observed Events (O)	% at 5 Year(s) (95% Cl)	Hazard ratio * (95% CI)	p-value **			
DFS	СТ	183	14	92.7 (86.8, 96.0)	0.69 (0.34,1.39)	0.297			
DF3	no CT	198	20	90.3 (84.6, 93.9)	1.00	0.297			
DMFS	СТ	183	9	96.3 (91.8, 98.3)	0.86 (0.35,2.14)	0.749			
DIVIES	no CT	198	11	94.1 (89.2, 96.9)	1.00	0.749			
OS	СТ	183	3	98.7 (94.7, 99.7)	0.45 (0.11,1.85)	0.267			
03	no CT	198	7	96.7 (92.7, 98.5)	1.00	0.207			

Legend: Because of the temporary shift in the 70-gene risk (from the 24th of May 2009 until the 30th of January 2010) all risk groups as enrolled are somewhat biased due to incorrect risk assessment in the full period (from end of May 2009 to January 2010). Therefore 2 additional patient populations (sensitivity analysis) were defined in the

SAP: one for the analyses of CT vs no CT in the discordant groups (PPS) and one for the primary test (PTS). These populations correspond to the PP1 and PT populations respectively, but exclude all patients enrolled during this G-risk shift period.

* Hazard ratios were calculated with the use of a Cox model after adjustment for the factors used in stratification for randomization assignments.

** values were calculated by means of the Wald test in the adjusted Cox Model.

4 Outcome in the 4 risk groups

	Corrected Risk	Patients	Observed Events	% at 5 Year(s) (95% Cl)
	C-low/G-low	2745	77	97.6 (96.9, 98.1)
DNAFC	C-low/G-high	592	32	94.8 (92.4, 96.4)
DMFS	C-high/G-low	1550	82	95.1 (93.8, 96.2)
	C-high/G-high	1806	171	90.6 (89.0, 92.0)
DFS	C-low/G-low	2745	211	92.8 (91.7, 93.7)
	C-low/G-high	592	58	90.3 (87.3, 92.6)
	C-high/G-low	1550	137	91.4 (89.7, 92.8)
	C-high/G-high	1806	266	85.3 (83.4, 87.0)
	C-low/G-low	2745	47	98.4 (97.8, 98.9)
05	C-low/G-high	592	19	97.2 (95.5, 98.3)
OS	C-high/G-low	1550	39	97.6 (96.6, 98.3)
	C-high/G-high	1806	103	94.7 (93.4, 95.7)

Table S 6: Outcome in terms of DMFS, DFS and OS for the 4 risk groups (per corrected risk)

	Type of first event*						
DMFS	distant metastasis	266 (73.5)					
DIVIFS	death	96 (26.5)					
	distant metastasis	242 (36.0)					
DFS	Loco-regional recurrence	110 (16.4)					
DF2	2nd primary cancer	282 (42.0)					
	death	38 (5.7)					


* Patients who experience multiple events at the same time (within a 1 month window), are classified into the first applicable category according to the following priority list:

- 1. distant metastases
- 2. locoregional recurrence
- 3. new 2nd primary cancer
- 4. death (due to any cause)

Legend: This figure reports the outcome in terms of DMFS, DFS and OS for the 4 risk groups C-low/G-low, C-low/G-high, C-high/G-low and C-high/G-high. The analysis includes all enrolled patients and the risk groups are based on corrected risk (Figure 1B).

5 Distant Metastasis Free Survival according to the genomic and clinical risk treatment strategy

Figure S 1: DMFS according to the genomic and clinical risk treatment strategy




Distant Metastasis Free Survival

Legend: This analysis estimates the outcome if all patients were treated according to C-risk or G-risk respectively. Using risk at time of enrollment, the C-risk strategy group consists of the groups C-low/G-low, C-low/G-high randomized to 'no CT', C-high/G-low randomized to 'CT' and C-high/G-high. The G-risk strategy consists of C-low/G-low, C-low/G-high randomized to 'CT', C-high/G-low randomized to 'no CT' and C-high/G-high. To have an unbiased estimate, the discordant patients (who were randomized) are doubly weighted, because they are underrepresented by a factor 2 in the resulting sample. Therefore comparison by means of classical statistical inference is incorrect and only the estimates of the 5-year DMFS are shown.

6 DMFS for CT versus no CT in the two discordant risk groups (ITT1 population), by nodal status


Figure S 2: DMFS CT versus no CT in the two discordant risk groups (ITT1 population) by nodal status A. C-high/G-low discordant risk group



Of note: the group of node-positive patients in the C- low/G-high group is too small to be analyzed

7 DMFS for CT versus no CT in the two discordant risk groups (ITT1 population), by tumor size

Figure S 3: DMFS CT versus no CT in the two discordant risk groups (ITT1 population) by tumor status A. C-high/G-low discordant risk group





8 Analyses within the subgroup of HR+/HER2-/LN0 patients

HR+/HER2-/LN0- subgroup						
Corrected risk (clinical/genomic)	Total (N=4225)					
	N (%)					
C-low/G-low	2464 (58.3)					
C-low/G-high	452 (10.7)					
C-high/G-low	716 (16.9)					
C-high/G-high	593 (14.0)					

Table S 7: Corrected risk in the subgroup of HR+/HER2-/LN0 patients

Legend: The HR+/HER2-/LN0 subgroup consists out of 4225 patients (63% of the AP population). Among the 4425 HR+/HER2-/LN0 patients, 3180 (75%) have a low genomic risk.

	HR+/HE	R2-/LN0 su	ıbgroup	
	Corrected risk	Patients (N)	Observed Events (O)	% at 5 Years (95% Cl)
	C-low/G-low	2464	193	92.7 (91.5, 93.7)
	C-low/G-high	452	43	90.6 (87.2, 93.2)
DFS	C-high/G-low	716	67	91.5 (89.1, 93.4)
	C-high/G-high	593	79	86.4 (83.0, 89.1)
	C-low/G-low	2464	68	97.6 (96.9, 98.2)
DNAES	C-low/G-high	452	26	94.3 (91.4, 96.3)
DMFS	C-high/G-low	716	44	94.9 (92.8, 96.3)
	C-high/G-high	593	56	90.9 (88.0, 93.2)
	C-low/G-low	2464	41	98.5 (97.8, 98.9)
OS	C-low/G-high	452	16	97.1 (94.9, 98.4)
US	C-high/G-low	716	22	97.0 (95.3, 98.1)
	C-high/G-high	593	30	95.5 (93.4, 96.9)
	C-low/G-low	2464	43	98.4 (97.8, 98.9)
	C-low/G-high	452	16	96.2 (93.7, 97.8)
DMFI*	C-high/G-low	716	35	96.3 (94.6, 97.5)
	C-high/G-high	593	48	91.8 (89.0, 93.9)

Table S 8: Outcome per corrected risk in the subgroup of HR+/HER2-/LN0 patients


* See section 10 for the definition of distant metastasis free interval (DMFI).

Table S 9: Outcome by genomic risk when following genomic treatment strategy (G-low versus G-high), in the
subgroup of HR+/HER2-/LN0 patients

	HR+/HER2-/LN0 subgroup							
	Genomic risk at enrollment	Allocated T strat		% at 5 Years				
DFS	Genomic Low	Follow g-risk	no ACT	92.0				
DFS	Genomic High	Follow g-risk	ACT	89.0				
DFMS	Genomic Low	Follow g-risk	no ACT	96.7				
DFIVIS	Genomic High	Follow g-risk	ACT	93.0				
OS	Genomic Low	Follow g-risk	no ACT	97.8				
US	Genomic High	Follow g-risk	ACT	96.1				
DMFI*	Genomic Low	Follow g-risk	no ACT	97.8				
	Genomic High	Follow g-risk	ACT	94.6				

* See section 10 for the definition of distant metastasis free interval (DMFI).

Legend: This analysis estimates the outcome for G-low patients and G-high patients, if all patients' chemotherapy decision would be decided by G risk (thus no chemo for G-low and chemo for G-high). To do this, all patients whose treatment allocation was consistent with such strategy are selected (so excluding the discordant ones who were randomized the other way). This analysis is similar to the one in Figure S1, but now reporting only for genomic risk, stratified by G-low versus G-high. To have an unbiased estimate, the discordant ones who were randomized into the strategy are doubly weighted, because they are underrepresented by a factor 2 in the resulting sample. No statistical inference between the two groups will be done (since randomized patients allocated to follow G-risk are doubly weighted), but the efficacy in both groups will be assessed by means of the 5-year estimate of DFS, DMFS, OS and DMFI.







Figure S 5: DMFS for CT versus no CT in the two discordant risk groups (ITT1 population), in the HR+/HER2-/LN0 subgroup



9 Multivariate analysis

Final model for DMFS (After backward selection) (N=6643)								
Factor	Levels	Interactions with chemo	Ν	I	Hazard Ratio (95% Cl)	P-value		
C-risk	low high		3325 3318		1.00 1.49 (1.05, 2.13)	0.026		
G-risk	low high		4273 2370		1.00 2.41 (1.79, 3.26)	<0.001		
LN status	LN- LN+		5253 1390		1.00 1.28 (0.99,1.67)	0.063		
T status	≤ 1 cm 1-2 cm 2-5 cm > 5cm		915 3853 1798 77		1.00 1.18 (0.78, 1.79) 1.92 (1.20, 3.06) 0.32 (0.04, 2.39)	<0.001		
CT and HER2 status interaction	HER2 negative HER2 positive	No CT CT No CT CT	5998 645	3654 2344 176 469	1.00 0.56 (0.40, 0.78) 1.00 0.24 (0.13,0.49)	CT effect: <0.001 HER2 effect: 0.967 Interaction effect between HER2 and CT: 0.012		
HR status	negative positive		1436 5207		1.00 0.82 (0.63, 1.05)	0.114		
grade	1 2 3		1487 3627 1529		1.00 1.49 (1.04, 2.13) 1.68 (1.08, 2.63)	0.060		
surgery	Mastectomy Breast conserving surgery		1205 5438		1.00 0.74 (0.58, 0.94)	0.015		

Table S 10: Multivariate analysis for DMFS in all enrolled patients

Legend: The focus of this analysis is on determining the extent to which 70-gene signature risk assessment may or may not replace other risk factors. Because key prognostic factors were used to decide on chemotherapy, chemotherapy (no CT, CT) will be included in all models below. In the population of all enrollment patients DMFS will be subjected to a full multivariate analysis, using the following conventions:

All variables listed below will be put into a multivariate Cox proportional hazards model, together with chemotherapy and chemotherapy-variable interactions, and the final model will be built using backward selection (until all p<0.05), while keeping chemotherapy and the factors to be retained (as listed below) in the model at all times. Variables will be included or excluded with their full categorization without regrouping or selection of categories.

The variables to be considered, and their categories, are:

- Age (<35, 35-49, 50-70)
- Baseline WHO performance status (WHO 0, WHO >0)


- Menopausal status
- Type of surgery (breast conserving surgery, radical mastectomy)
- Type of node evaluation (SNB, full axillary clearance)


The below variables will be retained in all models:

- Tumor size (0-1 cm, >1-2 cm, >2-5 cm, >5 cm)
- Differentiation (grade I, grade II, grade III)
- Nodal involvement (yes, no)
- HER-2 status (positive, negative)
- ER-PgR status (Positive (ER and/or PgR), Negative (both))
- Clinical-pathological risk assessment (C-risk) (low, high)
- 70-gene signature risk assessment (G-risk) (low, high)

The central pathology results for ER, PgR, HER2 and grade will be used when available (local pathology will be used otherwise). Patients with a missing value for any of the above factors are removed from the multivariate model when this model includes that factor.

10 Distant Metastasis Free Interval





Legend: For the endpoint of distant metastasis free interval (DMFI) only distant metastatic recurrences and deaths due to breast cancer progression or treatment toxicity will be considered events. Patients with unknown cause of death are also considered to have an event for DMFI. Patient with another cause of death (cardiovascular disease, other chronic disease, second primary cancer or other) are censored on their death date. If the patient is alive without an event, the censoring date will be the last examination date. Patients ineligible due to M1 status at baseline are censored at time 0 (1 patient).

11 Compliance to randomized treatment

	C-low/G-low (N=2745)	C-low/G-high (N=592)	C-high/G-low (N=1550)	C-high/G-high (N=1806)	Total (N=6693)
	N (%)	N(%)	N(%)	N (%)	N (%)
Freatment non-compliance					
no issue	2627 (95.7)	482 (81.4)	1244 (80.3)	1707 (94.5)	6059 (90.5)
Treatment allocation = CT but no CT given	0 (0.0)	58 (9.8) *	115 (7.4) **	71 (3.9)	244 (3.6)
Treatment allocation = no CT but CT given	37 (1.3)	36 (6.1) *	83 (5.4) **	0 (0.0)	156 (2.3)
Unknown whether CT given	3 (0.1)	4 (0.7)	9 (0.6)	19 (1.1)	35 (0.5)
Other	0 (0.0)	1 (0.2)	0 (0.0)	0 (0.0)	1 (0.0)
Risk change – compliance not defined	78 (2.8)	12 (2.0)	99 (6.4)	9 (0.5)	198 (3.0)
Reason Treatment allocation = CT but no CT given		N=58	N=115	N=71	N=244
patient refusal		52 (89.7)	95 (82.6)	64 (90.1)	211 (86.5)
PI decision		4 (6.9)	13 (11.3)	2 (2.8)	19 (7.8)
patient refusal + PI decision		0 (0.0)	3 (2.6)	1 (1.4)	4 (1.6)
ineligible		1 (1.7)	0 (0.0)	2 (1.8)	3 (1.2)
Other		1 (1.7)	4 (4.3)	2 (1.8)	7 (2.9)
Reason Treatment allocation = no CT but CT given	N=37	N=36	N=83		N=156
patient refusal	19 (51.4)	14 (38.9)	45 (54.2)		78 (50.0)
PI decision	13 (35.1)	19 (52.8)	26 (31.3)		58 (37.2)
patient refusal + PI decision	1 (2.7)	1 (2.8)	3 (3.6)		5 (3.2)
Missing	4 (10.8)	2 (5.6)	9 (10.8)		15 (9.6)

Table S 11: Compliance to randomized treatment as assessed by medical review

* 592 patients had corrected C-low/G-high risk.

Among those 592, 296 were allocated to CT at time of registration of which 58 were non-compliant (19.6%). Among those 592, 296 were allocated to no CT at time of registration of which 36 were non-compliant (12.2%). ** 1550 patients had corrected C-high/G-low risk.

Among those 1550, 793 were allocated to CT at time of registration of which 115 were non-compliant (14.5%). Among those 1550, 757 were allocated to no CT at time of registration of which 83 were non-compliant (11.0%).

Legend: The blue cells correspond to the patients that are considered non-complaint. For a clarification of the non-compliance rates in the C-low/G-high and C-high/G-low group refer to the footnotes * and **.

12 Agreement between local and central pathology

	Concordance (95% Cl)	Kappa (95% CI)	Positive Agreement	Negative Agreement	PPV	NPV	N
ER	97.8% (97.5 – 98.2)	0.897 (0.879 - 0.915)	98.2	94.8	99.3	87.3	5787
PgR	90.0% (90.2 – 91.7)	0.729 (0.707 – 0.750)	91.7	87.8	97.0	71.1	5734
HER2	96.6% (96.1 – 97.0)	0.796 (0.768 – 0.823)	80.4	98.2	82.5	98.0	5746

Table S 12: Agreement for all patients with available central pathology

13 Clinical risk assessment according to modified Adjuvant!Online

Table S 13: Classification of patients according to clinical risk assessment by the modified version of Adjuvant!Online

ER status	HER2 status	Grade	Nodal status	Tumor Size	Clinical Risk in Mindact
			N	≤ 3 cm	C-low
		well differentiated	N-	3.1-5 cm	C-high
		weir umerennateu	1-3 positive nodes	≤ 2 cm	C-low
ER positive	tive			2.1-5 cm	C-high
	HER2 negative		N-	≤ 2 cm	C-low
	R2 n	moderately differentiated		2.1-5 cm	C-high
	HEI		1-3 positive nodes	Any size	C-high
			N-	≤ 1 cm	C-low
R po		poorly differentiated or undifferentiated		1.1-5 cm	C-high
Ë			1-3 positive nodes	Any size	C-high
		well differentiated	N-	≤ 2 cm	C-low
	HER2 positive	OR	11-	2.1-5 cm	C-high
		moderately differentiated	1-3 positive nodes	Any size	C-high
			N	≤ 1 cm	C-low
		poorly differentiated or undifferentiated	N-	1.1-5 cm	C-high
			1-3 positive nodes	Any size	C-high
			N	≤ 2 cm	C-low
	ve	well differentiated	N-	2.1-5 cm	C-high
	2 negative		1-3 positive nodes	Any size	C-high
	32 ne	moderately differentiated		≤ 1 cm	C-low
ıtive	HER	OR poorly differentiated or	N-	1.1-5 cm	C-high
ER negative		undifferentiated	1-3 positive nodes	Any size	C-high
ER	ري ا			≤ 1 cm	C-low
	sitive	well differentiated OR	N-	1.1-5 cm	C-high
	HER2 positive	moderately differentiated	1-3 positive nodes	Any size	C-high
	HER	poorly differentiated or undifferentiated	Any	Any size	C-high

14 DMFS, DFS and OS for CT versus no CT in the two discordant risk groups (ITT1 population)

	C-high/G-low Intent-to-Treat population (ITT)								
	Treatment s followe	00	Patients (N)	Observed Events (O)	% at 5 Year(s) (95% CI)	Hazard Ratio* (95% CI)	p-value**		
DMFS	Follow c-risk	СТ	749	34	95.9 (94.0, 97.2)	0.78 (0.50,1.21)	0.267		
21110	Follow g-risk	no CT	748	46	94.4 (92.3, 95.9)	1.00	0.207		
DFS	Follow c-risk	СТ	749	54	92.9 (90.5, 94.7)	0.71 (0.50,1.01)	0.055		
DIS	Follow g-risk	no CT	748	78	90.1 (87.5, 92.1)	1.00			
OS	Follow c-risk	СТ	749	14	98.4 (97.0, 99.1)	0.69 (0.35,1.35)	0.278		
	Follow g-risk	no CT	748	22	97.0 (95.4, 98.1)	1.00	0.270		

Table S 14: DMFS, DFS and OS for CT versus no CT in the two discordant risk groups (ITT1 population).

	C-low/G-high Intent-to-Treat population (ITT)									
	Treatment s followe	00	Patients (N)	Observed Events (O)	% at 5 Year(s) (95% CI)	Hazard Ratio* (95% CI)	p-value**			
DMFS	Follow g-risk	СТ	344	18	95.8 (92.9, 97.6)	1.17 (0.59,2.28)				
DMIS	Follow c-risk	no CT	346	17	95.0 (91.8, 97.0)	1.00	0.657			
DFS	Follow g-risk	СТ	344	28	92.1 (88.3, 94.6)	0.87 (0.53,1.45)				
DL2	Follow c-risk	no CT	346	34	90.1 (86.1, 93.0)	1.00	0.603			
OS	Follow g-risk	СТ	344	11	97.1 (94.5, 98.5)	1.28 (0.54,3.02)	0.578			
03	Follow c-risk	no CT	346	10	97.8 (95.5, 99.0)	1.00	0.578			

Legend: These results compliment the Kaplan Meier curves in Figure 2 in the main paper.

* Hazard ratios were calculated with the use of a Cox model after adjustment for the factors used in stratification for randomization assignments.

** values were calculated by means of the Wald test in the adjusted Cox Model.


15 DMFS in the C-high/G-low risk group in the different analysis populations

Analysis Population (see main paper Figure 1)	Treatment strategy followed	Number of patients	Number of events	5-year distant- metastasis-free- survival (95% CI)	difference
Primary Test population	Genomic risk: No chemo	644	38	94.7% (92.5-96.2)	/
Intent-to-Treat	Genomic risk: No chemo	748	46	94.4% (92.3, 95.9)	1.5 %
population (C-high/G-low)	Clinical risk: chemo	749	34	95.9% (94.0, 97.2)	1.5 %
Per Protocol	Genomic risk: No chemo	636	37	94.8 (92.6, 96.3)	1.9%
population (C-high/G-low)	Clinical risk: chemo	592	22	96.7 (94.7, 98.0)	1.370

 Table S 15: DMFS the C-high/G-low risk group in the different analysis populations

16 The MINDACT study design

Figure S 7: The MINDACT study design.



Note that patient numbers for the risk groups correspond to the numbers in the corrected risk groups.

Legend: Patients with invasive early stage BC were screened for the trial. Eligible patients were women between ages 18 and 70, with histologically proven primary non-metastatic (M0) invasive BC (clinical T1, T2 or operable T3), initially LN0 only, and as of August 2009, up to 3 LN+. Clinical risk (C) was determined by a modified version of Adjuvant! Online (version 8.0 with HER2 status). Genomic risk (G) is determined by the 70-gene-signature. Patients with low-risk disease according to both C and G results were advised not to receive adjuvant CT, while for those with high-risk disease by both tests, CT was proposed. Patients with discordant results were randomized to have their treatment decision (R-T) based on either the C or the G result (i.e., CT or no CT). The R-T randomization used a

minimization technique stratified for institution, risk group (C-low/G-high vs. C-high/G-low), HR status (ER+ and/or PgR+ vs. ER and PgR neg), nodal involvement (yes, no), age (<50 vs. \geq 50), HER2 status (HER2+ vs. HER2 neg vs. unknown), axillary treatment (sentinel node only vs. dissection), and type of surgery (mastectomy vs. breast conservation). Two additional (optional) randomizations were implemented: patients assigned to adjuvant CT (either randomly due to discordant results or due to high-risk concordance of both tests) could be randomized to an anthracycline containing regimen or docetaxel plus capecitabine (R-C). The anthracycline arm was different for patients with LN0 BC and for patients with LN+ disease, as standard therapies were different for each subgroup at that time. For LN0 disease, anthracycline-based without taxanes regimens were used and included: FAC (cyclophosphamide, doxorubicin and 5-fluorouracil), FEC (cyclophosphamide, epirubicin and 5-fluorouracil), CAF (d1+8), CEF (d1+8) or E-CMF (4 cycles of single-agent epirubicin, followed by 4 cycles of cyclophosphamide, methotrexate, and fluorouracil (CMF)). For LN+ disease, the standard regimen was a sequence of 3 cycles of FEC 100 followed by 3 cycles of docetaxel.

Patients with HR+ BC could be further randomized to either 2 years of tamoxifen followed by 5 years of letrozole or 7 years of up-front letrozole (R-E). For this randomization, pre-menopausal women had to also receive a GnRH analogue.